The shares of Extended Stay America, Inc. (NASDAQ:STAY) has been pegged with a rating of Equal-Weight by Morgan Stanley in its latest research note that was published on August 9th, 2019. The research company has also assigned a $15 price target. Morgan Stanley wasn’t the only research firm that published a report of Extended Stay America, Inc., with other equities research analysts also giving their opinion on the stock. Jefferies advised investors in its research note published on August 8th, 2019, to Hold the STAY stock while also putting a $16 price target. The stock had earned Buy rating from Goldman when it published its report on March 4th, 2019. That day the Goldman set price target on the stock to $21. The stock was given Neutral rating by BofA/Merrill in its report released on October 23rd, 2018. Morgan Stanley was of a view that STAY is Overweight in its latest report on May 31st, 2018. Jefferies thinks that STAY is worth Buy rating. This was contained in the firm’s report on May 31st, 2018 in which the stock’s price target was also moved to $26.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $17.64. The price of the stock the last time has raised by 9.94% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 33.66.
The shares of the company added by 0.50% during the trading session on Thursday, reaching a low of $14.06 while ending the day at $14.16. During the trading session, a total of 1.38 million shares were traded which represents a 29.95% incline from the average session volume which is 1.97M shares. STAY had ended its last session trading at 14.09. Extended Stay America, Inc. currently has a market cap of $2.67B, while its P/E ratio stands at 24.71, while its P/E earnings growth sits at 2.15, with a beta of 1.14. Extended Stay America, Inc. debt-to-equity ratio currently stands at 2.89, while its quick ratio hovers at . STAY 52-week low price stands at $12.88 while its 52-week high price is $20.84.
The company in its last quarterly report recorded $0.32 earnings per share which is below the $0.33 predicted by most analysts. The Extended Stay America, Inc. generated $319.13 million in revenue during the last quarter, which is slightly lower than the $319.13 million predicted by analysts. In the second quarter last year, the firm recorded $0.16 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 50%. Extended Stay America, Inc. has the potential to record 0.57 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Needham published a research note on August 1st, 2019 where it informed investors and clients that Hologic, Inc. (NASDAQ:HOLX) is now rated as Buy. Their price target on the stock stands at $57. Jefferies also rated HOLX as Downgrade on August 8th, 2019, with its price target of $16 suggesting that HOLX could surge by 5.98% from its current share price. Even though the stock has been trading at $50.36/share, analysts expect it to surge higher by -1.01% to reach $53.02/share. It started the day trading at $50.65 and traded between $49.63 and $49.85 throughout the trading session.
A look at its technical shows that HOLX’s 50-day SMA is 48.88 while its 200-day SMA stands at 45.55. At the moment, only of Hologic, Inc. shares were sold short. The company’s average trading volume currently stands at 1.64M shares, which means that the short-interest ratio is just 3.19 days. Over the past seven days, the company moved, with its shift of 0.06%. Looking further, the stock has raised 11.57% over the past 90 days while it gained 6.15% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more HOLX shares, increasing its portfolio by +0.28% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 116,925 shares in the last quarter, thus it now holds 42,197,163 shares of HOLX, with a total valuation of $2,162,604,604. The Vanguard Group Inc meanwhile sold more HOLX shares in the recently filed quarter, changing its stake to $1,528,719,235 worth of shares. Capital Research Management Co followed the path by decreasing its HOLX portfolio by -7.74% in the quarter. This means that Capital Research Management Co sold -1,991,234 shares in the last quarter and now controls 23,733,989 shares of the HOLX stock, with the valuation hitting $1,216,366,936.
Similarly, BlackRock Fund Advisors increased its Hologic, Inc. shares by +3.24% during the recently filed quarter. After buying 435,421 shares in the last quarter, the firm now controls 13,894,939 shares of Hologic, Inc. which are valued at $712,115,624. In the same vein, Fidelity Management Research Co increased its Hologic, Inc. shares by during the most recent reported quarter. The firm bought 600,532 shares during the quarter which increased its stakes to 13,614,603 shares and is now valued at $697,748,404. Following these latest developments, around 0.70% of Hologic, Inc. stocks are owned by institutional investors and hedge funds.